SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer.

Greenlane Launches Eyce Glacier, Celebrates Brand’s 10th Anniversary

BOCA RATON, FL / ACCESSWIRE / July 13, 2023 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (NASDAQ:GNLN), one of the largest global sellers of

July 13, 2023

Boston Scientific to close Silk Road Medical headquarters, lay off 138 people

Boston Scientific will close Silk Road Medical’s headquarters in Sunnyvale, California, after it bought the maker of stroke prevention products in September. Spokesperson Chanel Hastings

October 29, 2024

Increased cannabis use in diabetics raises concerns about health risks

Researchers at University of California San Diego School of Medicine have found a significant increase in cannabis use among adults with diabetes in the United

July 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.